TY - JOUR
T1 - Heart Rate Reduction with Ivabradine Prevents Cardiac Rupture after Myocardial Infarction in Mice
AU - Ikeda, Masataka
AU - Ide, Tomomi
AU - Furusawa, Shun
AU - Ishimaru, Kosei
AU - Tadokoro, Tomonori
AU - Miyamoto, Hiroko Deguchi
AU - Ikeda, Soichiro
AU - Okabe, Kosuke
AU - Ishikita, Akihito
AU - Abe, Ko
AU - Matsushima, Shouji
AU - Tsutsui, Hiroyuki
N1 - Funding Information:
Masataka Ikeda, Tomomi Ide, Shun Furusawa, Kosei Ishimaru, Tomonori Tadokoro, Hiroko Deguchi Miyamoto, Soichiro Ikeda, Kosuke Okabe, Akihito Ishikita, Ko Abe, and Shouji Matsushima have nothing to declare. Hiroyuki Tsutsui received honoraria from Otsuka, Takeda Pharmaceutical, Mitsubishi-Tanabe Pharma, Daiichi Sankyo, Nippon Boehringer, Bayer Yakuhin, Pfizer, Novartis Pharma, Ono Pharmaceutical, MSD, Teijin Pharma, Bristol-Myers Squibb, and Astellas Pharma; manuscript fees from Medical View and Nippon Rinsho; and research funding from Nippon Boehringer, Mitsubishi-Tanabe Pharma, Japan Tobacco, Daiichi Sankyo, IQVIA Services Japan, Takeda Pharmaceutical, Bayer Yakuhin, Sanofi, Acterion Pharmaceuticals Japan, and MSD.
Funding Information:
This work was supported by JSPS KAKENHI (grant number 16H07049 and 18K15892 to MI, 17K09582 and 20K08426 to TI), the Takeda Science Foundation, the Uehara Memorial Foundation, the Japan Foundation for Applied Enzymology (VBIC: Vascular Biology of Innovation), the YOKOYAMA Foundation for Clinical Pharmacology (grant number YRY-1911), the MSD Life Science Foundation, the Public Interest Incorporated Foundation (MI), and AMED (grant number 20ek0109339h0003) (HT).
Publisher Copyright:
© 2021, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/4
Y1 - 2022/4
N2 - Purpose: Cardiac rupture is a fatal complication following myocardial infarction (MI). An increase in heart rate (HR) is reportedly an independent risk factor for cardiac rupture during acute MI. However, the role of HR reduction in cardiac rupture after MI remains to be fully elucidated. We aimed to evaluate the therapeutic efficacy of HR reduction with ivabradine (IVA) on post-MI cardiac rupture in mice. Methods: We induced MI in mice by ligating the left anterior descending coronary artery. Subsequently, we subcutaneously implanted osmotic pumps filled with IVA solution or vehicle (Veh) in the surviving MI mice at 24 h postoperatively. We biochemically analyzed the myocardium on day 5, additionally observed the mice for 10 days, and analyzed the rates of cardiac rupture and non-cardiac rupture death, and survival after MI. Results: HR was significantly lower in the IVA-treated mice, whereas blood pressure was comparable between the two groups. Compared to the Veh-treated mice, apoptosis was significantly reduced in the MI border zone in the IVA-treated mice. Although there were no differences in the infarct size of the surviving MI mice between the two groups, HR reduction with IVA significantly reduced cardiac rupture (rupture rate 26 and 8% in the Veh-treated and IVA-treated groups, respectively) and improved survival after MI. Conclusion: Our findings suggest that HR reduction with IVA prevents cardiac rupture after MI. This may be particularly effective in MI patients with a high HR who are either unable to adequately tolerate β-blockers or whose HR remains high despite receiving β-blockers.
AB - Purpose: Cardiac rupture is a fatal complication following myocardial infarction (MI). An increase in heart rate (HR) is reportedly an independent risk factor for cardiac rupture during acute MI. However, the role of HR reduction in cardiac rupture after MI remains to be fully elucidated. We aimed to evaluate the therapeutic efficacy of HR reduction with ivabradine (IVA) on post-MI cardiac rupture in mice. Methods: We induced MI in mice by ligating the left anterior descending coronary artery. Subsequently, we subcutaneously implanted osmotic pumps filled with IVA solution or vehicle (Veh) in the surviving MI mice at 24 h postoperatively. We biochemically analyzed the myocardium on day 5, additionally observed the mice for 10 days, and analyzed the rates of cardiac rupture and non-cardiac rupture death, and survival after MI. Results: HR was significantly lower in the IVA-treated mice, whereas blood pressure was comparable between the two groups. Compared to the Veh-treated mice, apoptosis was significantly reduced in the MI border zone in the IVA-treated mice. Although there were no differences in the infarct size of the surviving MI mice between the two groups, HR reduction with IVA significantly reduced cardiac rupture (rupture rate 26 and 8% in the Veh-treated and IVA-treated groups, respectively) and improved survival after MI. Conclusion: Our findings suggest that HR reduction with IVA prevents cardiac rupture after MI. This may be particularly effective in MI patients with a high HR who are either unable to adequately tolerate β-blockers or whose HR remains high despite receiving β-blockers.
UR - http://www.scopus.com/inward/record.url?scp=85098844645&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098844645&partnerID=8YFLogxK
U2 - 10.1007/s10557-020-07123-5
DO - 10.1007/s10557-020-07123-5
M3 - Article
C2 - 33411111
AN - SCOPUS:85098844645
SN - 0920-3206
VL - 36
SP - 257
EP - 262
JO - Cardiovascular Drugs and Therapy
JF - Cardiovascular Drugs and Therapy
IS - 2
ER -